Research Topics
Species | D Lawrence WickerhamSummaryAffiliation: National Surgical Adjuvant Breast and Bowel Project Country: USA Publications
| Collaborators
|
Detail Information
Publications
The use of tamoxifen and raloxifene for the prevention of breast cancerD Lawrence Wickerham
Operations Center, National Surgical Adjuvant Breast and Bowel Project, Allegheny Center, Pittsburgh, PA 15212, USA
Recent Results Cancer Res 181:113-9. 2009..51 vs 2.11 per 1,000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35-1.08)...
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel ProjectD Lawrence Wickerham
NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
Semin Oncol 35:522-9. 2008....- An update on breast cancer prevention trialsD L Wickerham
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, USA
Int J Gynecol Cancer 16:498-501. 2006..In this paper, we review the most prominent studies, all of which are either under way or in follow-up... - Breast cancer chemoprevention: progress and controversyD Lawrence Wickerham
National Surgical Adjuvant Breast and Bowel Project NSABP, Four Allegheny Center 5th Floor, Pittsburgh, PA 15212, USA
Surg Oncol Clin N Am 19:463-73. 2010..The agents of established value are important options for women today, and efforts are under way to identify additional more effective therapies... - The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel ProjectD Lawrence Wickerham
National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
World J Surg 30:1138-46. 2006.... - Tamoxifen--an update on current data and where it can now be usedLawrence Wickerham
National Surgical Adjuvant Breast and Bowel Project, Operations Center, Pittsburgh, PA, USA
Breast Cancer Res Treat 75:S7-12; discussion S33-5. 2002..In trials performed by the Swedish Breast Cancer Co-operative Group and the NSABP, the optimal duration of adjuvant tamoxifen therapy appears to be 5 years, although this is equivocal and not yet conclusively defined... - Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancerVictor G Vogel
NSABP, Pittsburgh, PA 15212, USA
Cancer Prev Res (Phila) 3:696-706. 2010..These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer... - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerSoonmyung Paik
Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
J Clin Oncol 24:3726-34. 2006..The relationship between the RS and chemotherapy benefit is not known... - Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20Eleftherios P Mamounas
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
J Clin Oncol 28:1677-83. 2010.... 
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Gong Tang
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, and Pathology Division, Pittsburgh, PA, USA
Breast Cancer Res Treat 127:133-42. 2011..219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit...- Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trialsReena S Cecchini
National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Center, One Sterling Plaza, 201 N Craig St, Suite 350, Pittsburgh, PA 15213, USA
Cancer Prev Res (Phila) 5:583-92. 2012.... - Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel
Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
JAMA 295:2727-41. 2006..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis... - Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)Carolyn D Runowicz
National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA
Am J Obstet Gynecol 205:535.e1-5. 2011..This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2 trial... - Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24D Craig Allred
National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
J Clin Oncol 30:1268-73. 2012..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen... - Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyBernard Fisher
Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
J Natl Cancer Inst 97:1652-62. 2005..Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings... - National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situVictor G Vogel
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
Clin Cancer Res 9:495S-501S. 2003..Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003... - Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas
National Surgical Adjuvant Breast and Bowel Project, Operations Office and Biostatistical Center, Pittsburgh, PA, USA
J Clin Oncol 23:3686-96. 2005.... - Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancerStewart J Anderson
Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
J Clin Oncol 27:2466-73. 2009..Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease... - Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
J Clin Oncol 24:2019-27. 2006..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)... - Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialStephanie R Land
National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
JAMA 295:2742-51. 2006..Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown... - Lower-category benign breast disease and the risk of invasive breast cancerJiping Wang
Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Natl Cancer Inst 96:616-20. 2004..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)... - Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trialNeil Abramson
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
J Natl Cancer Inst 98:904-10. 2006..However, the involvement of hypercoagulability factors in this association is unclear... - Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim
National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
J Clin Oncol 29:4160-7. 2011..We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors... - A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerSoonmyung Paik
Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
N Engl J Med 351:2817-26. 2004..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures... - Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or lessBernard Fisher
National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
J Clin Oncol 20:4141-9. 2002.... - Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention TrialsVictor G Vogel
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
J Natl Cancer Inst Monogr 2010:181-6. 2010..51 per 1000 women assigned to tamoxifen and 2.11 per 1000 women assigned to raloxifene (risk ratio, 1.40; 95% confidence interval = 0.98 to 2.00)... - Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention TrialStephanie R Land
National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, University of Pittsburgh, PA, USA
Cancer Prev Res (Phila) 4:1393-400. 2011..001; OR = 1.5 high vs. low) predicted adequate adherence at 36 months. There were no significant associations with obesity or physical activity. Alcohol use and smoking might indicate a need for greater adherence support... - Pathologic variables predictive of breast events in patients with ductal carcinoma in situEdwin R Fisher
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
Am J Clin Pathol 128:86-91. 2007..The similar predictive role of comedo necrosis in this study and that reported previously from NSABP B-17 (total of 2,079 patients) strongly supports its role as a simple high-risk predictor for ipsilateral breast tumor recurrences... - The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trialVictor G Vogel
The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA
Clin Breast Cancer 3:153-9. 2002..0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast.. - Is tamoxifen a risk factor for retinal vaso-occlusive disease?Michael B Gorin
Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Retina 25:523-6. 2005 - Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trialD Lawrence Wickerham
NSABP Operations Center, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
Recent Results Cancer Res 163:87-95; discussion 264-6. 2003..Its second prevention study, the STAR trial, is currently under way... - Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27Eleftherios P Mamounas
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
J Clin Oncol 23:2694-702. 2005..Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy... - Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experienceSoonmyung Paik
National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
J Natl Cancer Inst 94:852-4. 2002..This report provides a snapshot of the quality of HER2 assays performed in laboratories nationwide... - The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear
Virginia Commonwealth University, Medical College of Virginia School of Medicine, Richmond, VA, USA
J Clin Oncol 21:4165-74. 2003.... - Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trialEleftherios P Mamounas
Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
J Clin Oncol 26:1965-71. 2008.... - Effects of tamoxifen on benign breast disease in women at high risk for breast cancerElizabeth Tan-Chiu
Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
J Natl Cancer Inst 95:302-7. 2003..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women... - Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancerSandra M Swain
National Cancer Institute, Bethesda, MD, USA
J Natl Cancer Inst 96:516-23. 2004.... - Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifenWorta McCaskill-Stevens
CORE Investigators National Cancer Institute, National Institutes of Health, 6130 Executive Blvd, EPN 2014, Bethesda, MD 20892, USA
J Natl Cancer Inst 96:1762-9. 2004..Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women... - Prevention of hormone-related cancers: breast cancerBarbara K Dunn
National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892, USA
J Clin Oncol 23:357-67. 2005.... - Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancerJames J Dignam
Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
Breast Cancer Res Treat 97:245-54. 2006..Both obesity and estrogen receptor negative (ER-) tumors are more prevalent in black women than in whites in North America. We evaluated obesity and race in relation to outcomes in women with ER-breast cancer... - Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)Mary S Beattie
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
J Natl Cancer Inst 98:110-5. 2006..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population... - Benign gynecologic conditions among participants in the Breast Cancer Prevention TrialEva Chalas
Department of Obstetrics, Gynecology and Reproductive Medicine, Stony Brook University, State University of New York, Stony Brook, NY
Am J Obstet Gynecol 192:1230-7; discussion 1237-9. 2005..This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project... - Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyVictor G Vogel
J Natl Cancer Inst 94:1504. 2002 - Association of tamoxifen and uterine sarcomaD Lawrence Wickerham
J Clin Oncol 20:2758-60. 2002 - Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention TrialMary Cushman
Department of Medicine, University of Vermont, Burlington, VT, USA
Br J Haematol 120:109-16. 2003..Reductions of antithrombin and protein S, but not protein C or APC resistance, might relate to the increased risk of venous thrombosis associated with tamoxifen treatment...